Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIV-509 study of skin barrier function in atopic dermatitis
NL-OMON60222Phase 1Completed
- Sponsor
- Triveni Bio
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of TRIV-509 in atopic dermatitis (AD), sponsored by Triveni Bio. Started Oct 2025; status: completed.
02
Drugs
TRIV-509
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON60222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60222.